Want to see HK:1672 full AI Analyst Report?
1672 Stock Chart & Stats
HK$18.48
HK$0.09(3.03%)
At close: 4:00 PM EST
HK$18.48
HK$0.09(3.03%)
Day’s Range― - ―
52-Week RangeHK$8.49 - HK$19.86
Previous CloseN/A
Volume2.91M
Average Volume (3M)8.30M
Market Cap
HK$11.86B
Enterprise ValueHK$7.56B
Total Cash (Recent Filing)HK$1.90B
Total Debt (Recent Filing)HK$5.16M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 24, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding1,068,455,100
10 Day Avg. Volume6,104,199
30 Day Avg. Volume8,303,348
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)5.14
Price to Sales (P/S)4905.97
P/FCF Ratio-30.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.44
Revenue Forecast (FY)HK$804.38M
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company’s extremely low debt-to-equity provides durable financial flexibility and materially lowers near-term solvency risk. Over a 2–6 month horizon this reduces the likelihood of forced restructuring, gives room to raise capital on better terms, and supports continued operations while management attempts to stabilize revenues.
Diversified Revenue ModelAscletis generates revenue through commercial product sales plus collaboration and licensing income (upfronts, milestones, royalties). This multi-path monetization is a structural strength: partnerships can de-risk development, provide milestone liquidity, and allow value capture even if single-product sales lag.
Historic Gross Margin CapabilityPrior periods of positive gross margin indicate the company’s manufacturing and product economics can support profitable sales at scale. If revenue recovers or new products scale, the cost structure has shown it can deliver positive gross profitability rather than structural negative margins.
Bears Say
Collapsing Revenue BaseA severe, multi-year collapse in revenue materially weakens the company's core earnings power and market position. With a much smaller top line, fixed costs are harder to cover, commercial leverage is lost, and strategic options (pricing, distribution, R&D funding) become constrained absent durable revenue recovery.
Persistent And Accelerating Cash BurnSustained, large negative operating cash flow depletes reserves quickly and forces reliance on external financing or asset monetization. Even with low debt, accelerating cash burn threatens runway, limits investment in commercialization and R&D, and increases dilution or solvency risk over the medium term.
Eroding Equity And Poor ReturnsPersistent net losses that drive negative ROE and declining assets/equity indicate shareholder value erosion. This structural deterioration raises the company’s cost of capital, restricts strategic flexibility, and signals that operations are not currently generating sustainable returns without material operational or commercial change.
Ascletis Pharma, Inc. News
1672 FAQ
What was Ascletis Pharma, Inc.’s price range in the past 12 months?
Ascletis Pharma, Inc. lowest stock price was HK$8.49 and its highest was HK$19.86 in the past 12 months.
What is Ascletis Pharma, Inc.’s market cap?
Ascletis Pharma, Inc.’s market cap is HK$11.86B.
When is Ascletis Pharma, Inc.’s upcoming earnings report date?
Ascletis Pharma, Inc.’s upcoming earnings report date is Aug 24, 2026 which is in 43 days.
How were Ascletis Pharma, Inc.’s earnings last quarter?
Ascletis Pharma, Inc. released its earnings results on Mar 31, 2026. The company reported -HK$0.324 earnings per share for the quarter, the consensus estimate of -HK$0.324 by HK$0.
Is Ascletis Pharma, Inc. overvalued?
According to Wall Street analysts Ascletis Pharma, Inc.’s price is currently Overvalued.
Does Ascletis Pharma, Inc. pay dividends?
Ascletis Pharma, Inc. does not currently pay dividends.
What is Ascletis Pharma, Inc.’s EPS estimate?
Ascletis Pharma, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Ascletis Pharma, Inc. have?
Ascletis Pharma, Inc. has 1,068,455,100 shares outstanding.
What happened to Ascletis Pharma, Inc.’s price movement after its last earnings report?
Ascletis Pharma, Inc. reported an EPS of -HK$0.324 in its last earnings report, expectations of -HK$0.324. Following the earnings report the stock price went down -1.129%.
Which hedge fund is a major shareholder of Ascletis Pharma, Inc.?
Currently, no hedge funds are holding shares in HK:1672
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascletis Pharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
612.66%
12-Months-Change
Fundamentals
Return on Equity
-18.93%
Trailing 12-Months
Asset Growth
1.80%
Trailing 12-Months
Company Description
Ascletis Pharma, Inc.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---